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University Hospital's (NSUH) Center for International Blood
and Marrow Transplant Research (CIBMTR) data to describe
the relapse and survival of our diffuse large cell lymphoma
patients in second remission / response undergoing high
dose chemotherapy and autologous stem cell transplantation
from December 2007 to March 2012.
Our primary aimwas to evaluate overall and progression-
free survival at 100 days and 1 year post transplant.
Descriptive statistics (mean, standard deviation, frequencies
and proportions) were calculated for demographics and
clinical factors. The Kaplan-Meier product-limit method was
used to estimate OS and PFS. Subjects inwhich the outcomes
of interest (death or progression) were not observed were
considered censored using their last date of follow-up.
This analysis consisted of 29 patients; mean age 57.85
years. The 100-day and one year overall survival rates were
89.66% and 67.81%, respectively. The 100-day and one year
progression free survival rates were 78.57% and 73.33%,
respectively. Among those patients who died, the primary
causes of death were bacterial infection, recurrence of
primary disease, and cardiac failure.
These outcomes appear comparable to those provided by
the Center for International Blood and Marrow Transplant
Research. Thus allowing us to conclude that Augmented CBV
is a viable preparative regimen for patients with relapsed
diffuse large cell lymphoma undergoing autologous stem cell
transplantation.243
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Sarcopenia is a state of abnormally low muscle mass that
is associated with more treatment-related complications,
shorter time to recurrence or progression, and shorter overall
survival in patients with different cancers, including
lymphoma, pancreatic, lung, and breast cancer. Sarcopenia is
a potentially modiﬁable host factor that can be easily and
reliably obtained from routine computerized tomography
(CT). The objective of this study is to determine whether
sarcopenia impacts transplant-related outcomes in patients
undergoing autologous and allogeneic hematopoietic stem
cell transplantation (HSCT) for Hodgkin's lymphoma (HL) or
non-Hodgkin's lymphoma (NHL). Patients transplanted
between 6/2005 and 6/2012 at the University of Michigan
BMT Program were eligible for inclusion if a CT of the
abdomen was performed within 60 days prior to HSCT.
Cross-sectional area and density of the psoas muscles at the
level of the fourth lumbar vertebra were calculated. Lean
psoas muscle mass accounting for fatty inﬁltration was
determined using algorithms programmed in the Analytic
Morphomics Lab at the University of Michigan.
Results: Total psoas area and lean psoas area were calculated
for 121 autologous transplant patients who met inclusion
criteria. The median total psoas area/height was 1255.2
mm2/m and the median lean psoas area/height was 977.4
mm2/m. After controlling for age and gender, the hazard ratio
for non-relapse mortality (NRM)was 0.79 (C.I. 0.60,1.05), P¼.088 for every 100mm2/m increase in total psoas area/height
and 0.75 (C.I. 0.55, 1.04), P ¼ .099 for every 100 mm2/m
increase in lean psoas area/height. Patients were then
divided into tertiles for total psoas area/height and lean
psoas area/height. Since only one NRM event was observed
among included women and occurred in a woman in the
lowest tertile for total psoas area/height and lean psoas area/
height, the tertile anlaysis was conducted in only men.
Among all included men, a greater NRM was seen in the
patients in the bottom two tertiles, compared to the tertile
with the greatest muscle mass and can be observed in the
attached ﬁgure (P ¼ .02 and P ¼ .03 for a log-rank test of the
lowest and middle tertile respectively). In the 43 allogeneic
transplants, sarcopenia had no impact on outcome.
Conclusion: Patients with a greater degree of pre-transplant
sarcopenia who underwent an autologous HSCT for NHL or
HL had a greater risk of NRM than those with greater muscle
mass. CT-determined psoas muscle mass may be a valuable
addition to comorbidity indices used to guide optimal
treatment selection and serve as a potentially modiﬁable
host factor to improve transplant-related outcomes. This
difference was not noted in the allogeneic transplant pop-
ulation, where a different and more complex set of compli-
cations may come into play, although this requires
conﬁrmation in a larger sample.
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Background: Immunoglobulin light chain amyloidosis (AL)
is characterized by deposition of insoluble ﬁbrils composed
of immunoglobulin light chains, causing progressive organ
dysfunction. Renal involvement is seen in 50% of cases of AL,
which, if left untreated, progresses to end-stage renal disease
(ESRD).
Methods: We performed a retrospective analysis in 75
patients (pts) with AL with renal involvement who under-
went high-dose chemotherapy and autologous hematopoi-
etic stem cell transplantation (auto-HCT) at our institution
between 1999 and 2011. Fifty-ﬁve of these AL pts had
renal involvement, as deﬁned by the International
Consensus Criteria (Ref. Gertz M et al. AJH 2005). Primary
objectives were to assess hematologic and organ response,
